Mo Ney schreef op 22 december 2010 08:48:
[...]
In June 2006, Galapagos signed a broad alliance with GSK to discover and develop breakthrough medicines for
osteoarthritis. This multi-target, multi-year alliance runs from target discovery through to delivery of a clinical
proof of concept. The alliance was expanded thrice (in June 2007, December 2008, and December 2009) since
commencement. Based on these expansions, the alliance is now worth more than € 200 mn in total payments
from the alliance. Royalties on global sales are in double digits. The alliance earlier included three drug
candidates which were - GLPG0555, GLPG0634 and GLPG0778.
www.vanleeuwenhoeck.com/upload/conten... slide 14